Zentalis Pharmaceuticals
ZNTL· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -55.4% in FY2025
Julie Eastland is the CEO of Zentalis Pharmaceuticals and was paid $1.3M in FY2025 (Dec), down 84%.
Pay$100 in the stock at the end of FY23 → $9
Executives5
See all- 1Andrea PaulFormer Chief Legal Officer and Corporate SecretaryFY2025
- 2Julie EastlandPresident and Chief Executive OfficerFY2025
- 3Mark Lackner, Ph.D.Former Chief Scientific OfficerFY2025
- 4Ingmar Bruns, M.D.Chief Medical OfficerFY2025
- 5James BucherChief Legal Officer and Corporate SecretaryFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allZentalis Pharmaceuticals paid its 5 named executives $7.0M in total in FY2025 (Dec). CEO Julie Eastland was paid $1.3M of that.
| Name | |||
|---|---|---|---|
| Andrea PaulFormer Chief Legal Officer and Corporate Secretary | Not disclosed | Not disclosed | |
| Julie EastlandPresident and Chief Executive Officer | Not disclosed | ||
| Mark Lackner, Ph.D.Former Chief Scientific Officer | Not disclosed | ||
| Ingmar Bruns, M.D.Chief Medical Officer | Not disclosed | Not disclosed | |
| James BucherChief Legal Officer and Corporate Secretary | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers23
See allThe comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board2
See all- David JohnsonDirector · 5 yr on the boardIndependentCompensation (Chair)—Paid as an executive
- Luke Walker, M.D.Director · 1 yr on the boardIndependentAudit, Nominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 30, 2026 | FY2025 |
| Annual report | 10-K | Mar 26, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 30, 2025 | FY2024 |
| Annual report | 10-K | Mar 26, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 29, 2024 | FY2023 |
| Annual report | 10-K | Feb 27, 2024 | FY2023 |